Ara
Toplam kayıt 6, listelenen: 1-6
Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy
(Akad Doktorlar Yayinevi, 2021)
Left-sided (LCC) and right-sided (RCC) colon cancers have different prognostic and predictive features in metastatic colon cancers, however there is insufficent data about tumor location in stage III disease. The aim of ...
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
(Springer, 2020)
Introduction: Although several clinical factors which show the benefit of adjuvant chemotherapy (AC) in early-stage colon cancer use for evaluating the risk of relapse, there is no consensus on which risk factors are more ...
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
(Springer, 2021)
Purpose Colorectal cancer is the third leading diagnosis accounting for nearly 10% of all new cancers worldwide. The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists. ...
Prognostic role of pre-operative serum ferritin level in stage 2 colon cancer
(Verduci, 2021)
OBJECTIVE: In this study, we aimed to evaluate the prognostic value of preoperative serum ferritin level in patients with stage 2 colon cancer who underwent curative surgery.
PATIENTS AND METHODS: The data of 120 patients ...
A New Prognostic Index in Young Breast Cancer Patients
(College of Physicians and Surgeons Pakistan, 2022)
Objective:To evaluate the prognostic role of pan immune-inflammation value (PIV) in young breast cancer patients.
Study Design: Descriptive study.
Place and Duration of Study: Department of Medical Oncology, Afyon ...
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
(Lippincott, Williams & Wilkins, 07.06.2022)
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...